Copyright
©The Author(s) 2025. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Gastrointest Oncol. Jan 15, 2025; 17(1): 93983
Published online Jan 15, 2025. doi: 10.4251/wjgo.v17.i1.93983
Published online Jan 15, 2025. doi: 10.4251/wjgo.v17.i1.93983
Antiviral therapy for hepatitis B virus infection is beneficial for the prognosis hepatocellular carcinoma
Hui Wan, Yu-Xin Zhang, Guan-Yue Shan, Jun-Ya Cheng, Duan-Rui Qiao, Yi-Ying Liu, Wen-Na Shi, Institute of Translational Medicine, The First Hospital of Jilin University, Changchun 130061, Jilin Province, China
Jun-Ya Cheng, Duan-Rui Qiao, Yi-Ying Liu, Wen-Na Shi, Department of Bioengineering, Pharmacy School of Jilin University, Changchun 130061, Jilin Province, China
Hai-Jun Li, Institute of Liver Diseases, Institute of Translational Medicine, The First Hospital of Jilin University, Changchun 130061, Jilin Province, China
Author contributions: Zhang YX, Shan GY, Qian DR, and Shi WN collected the information; Cheng JY and Liu YY drew and modified the illustrations; Wan H wrote the paper; Li HJ revised the paper.
Supported by the Natural Science Foundation of China , No. 81970529 ; the Natural Science Foundation of Jilin Province , No. 20230508074RC and No. YDZJ202401218ZYTS .
Conflict-of-interest statement: The authors declare that they have no conflict of interest.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Hai-Jun Li, MD, PhD, Associate Professor, Institute of Liver Diseases, Institute of Translational Medicine, The First Hospital of Jilin University, No. 71 Xinmin Street, Changchun 130061, Jilin Province, China. hjli2012@jlu.edu.cn
Received: March 9, 2024
Revised: September 20, 2024
Accepted: September 29, 2024
Published online: January 15, 2025
Processing time: 278 Days and 4.9 Hours
Revised: September 20, 2024
Accepted: September 29, 2024
Published online: January 15, 2025
Processing time: 278 Days and 4.9 Hours
Core Tip
Core Tip: Hepatocellular carcinoma (HCC) is the seventh most common cancer in the world and is usually associated with hepatitis B virus (HBV) infection. Radical resection and antiviral therapy are considered key clinical treatments for patients with HBV-related HCC. However, many patients have their HCC and HBV infection detected at the same time, so they receive remedial antiviral treatment beginning in the perioperative period, missing the opportunity for long-term preoperative antiviral therapy. Therefore, evaluating the clinical efficacy and relevant factors of perioperative remedial antiviral therapy will be valuable.